Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics (VRDN) has announced the approval of inducement grants for 15 new employees, consisting of non-qualified stock options to purchase 527,750 shares of common stock. The grants, approved on February 3, 2025, were made outside the company's Amended and Restated 2016 Equity Incentive Plan but follow its terms.
The options' exercise price equals the closing price on the grant date and will vest over four years, with 25% vesting after one year and the remainder vesting in 36 monthly installments. The company is currently advancing multiple candidates for thyroid eye disease (TED), including veligrotug (VRDN-001) and VRDN-003, both reporting positive results in phase 3 trials. Additionally, Viridian is developing novel FcRn inhibitors VRDN-006 and VRDN-008 for potential autoimmune disease treatments.
Viridian Therapeutics (VRDN) ha annunciato l'approvazione di incentivi per 15 nuovi dipendenti, consistenti in opzioni su azioni non qualificate per l'acquisto di 527.750 azioni ordinarie. Gli incentivi, approvati il 3 febbraio 2025, sono stati concessi al di fuori del Piano di Incentivazione Azionaria Ampliato e Riformato del 2016 dell'azienda, ma seguono i suoi termini.
Il prezzo di esercizio delle opzioni è pari al prezzo di chiusura alla data di concessione e maturerà nell'arco di quattro anni, con il 25% che matura dopo un anno e il resto in 36 rate mensili. Attualmente, l'azienda sta sviluppando più candidati per la malattia oculare tiroidea (TED), inclusi veligrotug (VRDN-001) e VRDN-003, entrambi con risultati positivi nei trial di fase 3. Inoltre, Viridian sta sviluppando nuovi inibitori dell'FcRn, VRDN-006 e VRDN-008, per potenziali trattamenti delle malattie autoimmuni.
Viridian Therapeutics (VRDN) ha anunciado la aprobación de incentivos para 15 nuevos empleados, que consisten en opciones sobre acciones no calificadas para la compra de 527.750 acciones ordinarias. Los incentivos, aprobados el 3 de febrero de 2025, se realizaron fuera del Plan de Incentivos de Capital Ampliado y Reformado de 2016 de la compañía, pero siguen sus términos.
El precio de ejercicio de las opciones es igual al precio de cierre en la fecha de concesión y se vestirá a lo largo de cuatro años, con el 25% vistiéndose después de un año y el resto en 36 pagos mensuales. Actualmente, la compañía está avanzando con múltiples candidatos para la enfermedad ocular tiroidea (TED), incluyendo veligrotug (VRDN-001) y VRDN-003, ambos reportando resultados positivos en ensayos de fase 3. Además, Viridian está desarrollando nuevos inhibidores de FcRn, VRDN-006 y VRDN-008, para posibles tratamientos de enfermedades autoinmunes.
비리디안 테라퓨틱스 (VRDN)는 15명의 새로운 직원에게 비자격 주식 옵션을 통한 유인 보상을 승인했다고 발표했습니다. 이 보상은 527,750주를 구매할 수 있는 옵션으로 구성되며, 2025년 2월 3일에 승인되었습니다. 이 보상은 회사의 변경 및 개정된 2016년 자본 인센티브 계획과는 별개로 이루어졌지만, 그 조건을 따릅니다.
옵션의 행사 가격은 부여일의 종가와 같으며, 4년 동안 단계적으로 행사됩니다. 1년 후에 25%가 발생하고 나머지는 36개월에 걸쳐 발생합니다. 현재 이 회사는 갑상선 안병(TED)을 위한 여러 후보물질을 진행 중이며, 여기에는 벨리그로탁(VRDN-001)과 VRDN-003이 포함되어 있으며, 두 후보 모두 3상 시험에서 긍정적인 결과를 보고했습니다. 또한 비리디안은 잠재적인 자가면역 질환 치료를 위한 새로운 FcRn 억제제인 VRDN-006과 VRDN-008을 개발하고 있습니다.
Viridian Therapeutics (VRDN) a annoncé l'approbation de subventions incitatives pour 15 nouveaux employés, qui consistent en des options d'achat d'actions non qualifiées pour acquérir 527.750 actions ordinaires. Les subventions, approuvées le 3 février 2025, ont été accordées en dehors du Plan d'Incentives en Actions Modifié et Restauré de 2016 de la société, mais respectent ses termes.
Le prix d'exercice des options est égal au prix de clôture à la date de subvention et se libérera sur quatre ans, avec 25% se libérant après un an et le reste en 36 versements mensuels. Actuellement, la société fait progresser plusieurs candidats pour la maladie oculaire thyroïdienne (TED), y compris veligrotug (VRDN-001) et VRDN-003, qui rapportent tous deux des résultats positifs lors des essais de phase 3. De plus, Viridian développe de nouveaux inhibiteurs de FcRn, VRDN-006 et VRDN-008, pour des traitements potentiels de maladies auto-immunes.
Viridian Therapeutics (VRDN) hat die Genehmigung von Anreizgewährungen für 15 neue Mitarbeiter bekannt gegeben, die aus nicht qualifizierten Aktienoptionen zum Kauf von 527.750 Stammaktien bestehen. Die Genehmigungen, die am 3. Februar 2025 erteilt wurden, erfolgten außerhalb des geänderten und neu gefassten Aktienoptionsplans von 2016 der Gesellschaft, folgen jedoch dessen Bedingungen.
Der Ausübungspreis der Optionen entspricht dem Schlusskurs am Zuteilungstag und wird über vier Jahre fällig, wobei 25 % nach einem Jahr und der Rest in 36 monatlichen Raten fällig wird. Das Unternehmen entwickelt derzeit mehrere Kandidaten für die autoimmune Augenerkrankung (TED), darunter veligrotug (VRDN-001) und VRDN-003, die beide positive Ergebnisse in Phase-3-Studien berichten. Darüber hinaus entwickelt Viridian neuartige FcRn-Hemmer, VRDN-006 und VRDN-008, zur Behandlung möglicher Autoimmunerkrankungen.
- Positive topline data reported from both THRIVE and THRIVE-2 phase 3 trials for veligrotug
- Multiple drug candidates in advanced clinical stages for TED treatment
- Diversified pipeline including FcRn inhibitors for autoimmune diseases
- None.
The Inducement Grants have an exercise price per share that is equal to the closing price of Viridian’s common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with
About Viridian Therapeutics
Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for veligrotug (VRDN-001), including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED. Both THRIVE and THRIVE-2 reported positive topline data, meeting all the primary and secondary endpoints of each study. Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients with active and chronic TED.
In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Viridian is based in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250206583715/en/
Anabel Chan, 617-458-8725
Vice President, Investor Relations & Communications
IR@viridiantherapeutics.com
Louisa Stone, 617-272-4604
Manager, Investor Relations
IR@viridiantherapeutics.com
Source: Viridian Therapeutics, Inc.
FAQ
How many shares were included in VRDN's February 2025 inducement grants?
What is the vesting schedule for VRDN's February 2025 inducement grants?
What were the results of VRDN's THRIVE and THRIVE-2 clinical trials?
What are the main drug candidates in VRDN's thyroid eye disease portfolio?
What additional therapeutic areas is VRDN developing drugs for?
